Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Cash from Financing Activities (2018 - 2025)

Historic Cash from Financing Activities for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to $2.2 million.

  • 10x Genomics' Cash from Financing Activities fell 5036.53% to $2.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $6.8 million, marking a year-over-year decrease of 3766.72%. This contributed to the annual value of $6.8 million for FY2025, which is 3766.72% down from last year.
  • 10x Genomics' Cash from Financing Activities amounted to $2.2 million in Q4 2025, which was down 5036.53% from $617000.0 recorded in Q3 2025.
  • In the past 5 years, 10x Genomics' Cash from Financing Activities registered a high of $16.2 million during Q2 2021, and its lowest value of -$3.4 million during Q1 2023.
  • Over the past 5 years, 10x Genomics' median Cash from Financing Activities value was $3.9 million (recorded in 2023), while the average stood at $4.1 million.
  • In the last 5 years, 10x Genomics' Cash from Financing Activities crashed by 24124.95% in 2023 and then soared by 29551.28% in 2025.
  • Quarter analysis of 5 years shows 10x Genomics' Cash from Financing Activities stood at $8.9 million in 2021, then crashed by 43.83% to $5.0 million in 2022, then rose by 12.24% to $5.6 million in 2023, then fell by 19.53% to $4.5 million in 2024, then tumbled by 50.37% to $2.2 million in 2025.
  • Its Cash from Financing Activities was $2.2 million in Q4 2025, compared to $617000.0 in Q3 2025 and $3.5 million in Q2 2025.